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stereotactic and conventional lung volumetric
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Petra S Kroon1*, Sandra Hol2 and Marion Essers1Abstract
Introduction: The main aim of the current study was to assess the dosimetric accuracy and clinical quality of
volumetric modulated arc therapy (VMAT) plans for stereotactic (stage I) and conventional (stage III) lung cancer
treatments planned with Eclipse version 10.0 Anisotropic Analytical Algorithm (AAA) and Acuros XB (AXB) algorithm.
Methods: The dosimetric impact of using AAA instead of AXB, and grid size 2.5 mm instead of 1.0 mm for VMAT
treatment plans was evaluated. The clinical plan quality of AXB VMAT was assessed using 45 stage I and 73 stage III
patients, and was compared with published results, planned with VMAT and hybrid-VMAT techniques.
Results: The dosimetric impact on near-minimum PTV dose (D98%) using AAA instead of AXB was large (underdose
up to 12.3%) for stage I and very small (underdose up to 0.8%) for stage III lung treatments. There were no
significant differences for dose volume histogram (DVH) values between grid sizes. The calculation time was
significantly higher for AXB grid size 1.0 than 2.5 mm (p < 0.01). The clinical quality of the VMAT plans was at least
comparable with clinical qualities given in literature of lung treatment plans with VMAT and hybrid-VMAT
techniques. The average mean lung dose (MLD), lung V20Gy and V5Gy in this study were respectively 3.6 Gy, 4.1%
and 15.7% for 45 stage I patients and 12.4 Gy, 19.3% and 46.6% for 73 stage III lung patients. The average
contra-lateral lung dose V5Gy-cont was 35.6% for stage III patients.
Conclusions: For stereotactic and conventional lung treatments, VMAT calculated with AXB grid size 2.5 mm
resulted in accurate dose calculations. No hybrid technique was needed to obtain the dose constraints. AXB is
recommended instead of AAA for avoiding serious overestimation of the minimum target doses compared to the
actual delivered dose.
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Volumetric modulated arc therapy (VMAT) has been
shown to be a powerful technique for irradiation of many
treatment sites with obtaining higher dose conformity to
the tumor while decreasing intra-fraction movements
because of shorter delivery times [1-8]. Reliable and accu-
rate dose delivery can be obtained using VMAT as shown
by pre-treatment dosimetric plan validations [9]. VMAT* Correspondence: kroon.p@bvi.nl
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reproduction in any medium, provided the orcould achieve at least comparable clinical plan qualities
and skin dose levels than intensity modulated radio-
therapy (IMRT) [10-12] and can successfully be used for
stereotactic body radiotherapy (SBRT) for patients with
stage I Non-Small-Cell Lung Cancer (NSCLC) [2,3,5].
In case of stage III large tumor lung cancers, it is diffi-
cult to limit doses to organs at risks (OARs) such as heart
and lung. High doses are preferred since local control in-
creased significantly (p = 0.02) when patients are treated
with higher doses than 64 Gy [13]. Rengan et al. [13]
stated that the median survival time for patients treated to
64 Gy or higher was 20 months versus 15 months fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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niques, IMRT and VMAT, have been shown to be able to
increase the therapeutic dose with equal toxicity profiles
compared to three-dimensional conformal radiotherapy
(3DCFRT) [14]. Unfortunately, it is not always possible to
deliver doses higher than 60 Gy to the planning target
volume (PTV) using 3DCFRT, IMRT and VMAT because
of dose limiting organs [14]. De Bree-Balk et al. [14] stated
that possibly further improvements could be made by
using hybrid techniques which combine two static fields
with IMRT or VMAT, as also investigated by Verbakel
et al. [15], who made a comparison between conventional
static field plans, IMRT, hybrid-IMRT, VMAT and hybrid-
VMAT; and by Chan et al. [16], who compared between
3DCFRT, VMAT and hybrid-VMAT. In both studies the
VMAT plans consisted of at least 2 arcs and the hybrid
plans of a combination of two static fields and IMRT or
VMAT. They have concluded that hybrid techniques are
superior in dosimetric outcomes for treating stage III lung
tumours compared to the other techniques. The treat-
ment planning for these studies has been performed using
Varian Eclipse treatment planning version 8 or 10 with
Anisotropic Analytical Algorithm (AAA).
We have recently introduced the Varian Eclipse software
version 10, with the AAA as well as the Acuros XB (AXB)
algorithm for photon dose calculations in our institute.
AXB solves the linear Boltzmann transport equation e.g.,
[17]. The dosimetric accuracy of AXB has already been in-
vestigated in several studies [18-22]. Fogliata et al. [19,21]
have concluded that AXB gives acceptable characteristics
in homogeneous media for small and large fields (range
0.8×0.8 to 40.0×40.0 cm2) using comparisons of AXB with
AAA and measurements. In heterogeneous situations, the
AXB algorithm has been shown to provide a valid and ac-
curate alternative to Monte Carlo calculations for field
sizes ranging from 2.5×2.5 to 30.0×30.0 cm2 [18,20,22].
Immediately after clinical introduction of the Varian
Eclipse software, we also clinically introduced VMAT for
lung SBRT stage I NSCLC as well as for lung stage III
treatments. For this clinical introduction, we investigated
the dosimetric accuracy and quality of stereotactic and
conventional VMAT planning in Eclipse using AXB and
AAA. Routinely, for all our patients, we perform pre-
treatment verification measurements using an ionization
chamber in the isocentre, combined with film measure-
ments in the isocentre plane.
It was already shown by Gete et al. [23] that AAA cal-
culations can slightly overestimate the minimum PTV
dose relative to Monte Carlo calculations with BEAMnrc/
DOSXYZnrc for stage I lung tumors (PTV range between
19 to 62 cm3) with forward planning with multiple static
non-coplanar conformal fields. It has also been shown by
VMAT comparison studies that AXB leads to a slightly
more accurate dose distribution than AAA [24,25]. Forstage III lung tumors (average PTV 690 cm3), Fogliata et al.
[26] have illustrated that AAA leads to a monitor unit
underestimation of approximately 1-2% relative to AXB
grid size 2.5 mm using a treatment planning comparison
between 3DCFRT, IMRT and VMAT.
Consequently, this suggests that AAA could overesti-
mate the minimum target dose, which leads to lower
target coverage than the prescribed dose, in case AXB
represents the real dose distribution. Kan et al. [27] have
illustrated that AXB was more accurate in predicting
secondary build-up near and beyond air/tissue interfaces
than AAA, using a comparison with measurements.
Bush et al. [22] have shown that AXB was capable of
modelling radiotherapy dose deposition in the low dens-
ity regions. Dose distributions calculated by AXB were
in good agreement with BEAMnrc/DOSXYZnrc Monte
Carlo dose calculations.
The purpose of this study was threefold. First, we
wanted to justify the assumption that AXB represents bet-
ter the real dose distribution than AAA by cross-checking
the finding of Bush et al. [22] with measurements, for
calculation grid sizes of 1.0 mm and 2.5 mm. Second, we
investigated the dosimetric impact of using AAA instead
of AXB, and grid size 2.5 mm instead of 1.0 mm for
VMAT treatment plans for stage I and stage III lung
tumors. Third, we investigated whether using AXB calcu-
lations in Eclipse version 10.0, VMAT results in improved
treatment plans compared to VMAT and hybrid-VMAT
plans published in literature, again for stage I (lung stereo-
tactic) and stage III (conventional lung) treatments.
Methods
Dose calculations
All calculations were performed using the treatment
planning system (TPS) Eclipse version 10 with beam
algorithms AAA and AXB (Varian Medical Systems,
Palo Alto, CA), which was installed on a standard
clinical workstation (Dell T5500) with dual 2.40 GHz
quad-core Intel processors (E5620), 24 GB RAM, and a
64 bit Windows 7 operating system, in a distributed
calculation framework (DCF) network of 3 worksta-
tions. The dose reporting mode dose-to-medium Dm
was selected for AXB.
Justification of the assumption that AXB represents the
real dose distribution
Before performing the main parts of our study, we vali-
dated the findings of Bush et al. [22] that AXB repre-
sents the actual dose delivery by performing percentage
depth dose (PDD) measurements using EBT2 film (ISP,
Wayne, NJ) in a simple heterogeneous interface phan-
tom, which consisted of three layers: upper and lower of
polystyrene with a density of ρ = 1.05 g cm-3 and thick-
ness of 5 and 7 cm, respectively, and a middle layer of
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of 8 cm. This very low density was chosen to investigate
the accuracy of both algorithms in a very extreme situ-
ation analogue to Bush et al. [22]. The measurements and
Eclipse dose calculations were performed for a field size of
1.0×1.0 cm2 and 4.0×4.0 cm2 using a 6 MV photon beam
(Clinac 2100iX equipped with a Millenium 120-MLC,
Varian Medical Systems, Palo Alto, CA) of 200 monitor
units and a source to skin distance (SSD) of 100 cm.
Patient selection
Eight stage I and seven stage III lung patients were se-
lected to investigate the dosimetric impact of using
AAA instead of AXB, and grid size 2.5 mm instead of
1.0 mm, for dose calculations of VMAT treatment plans.
The average PTV volume was 24.0 cm3 (range 5.1 to
56.9 cm3) for stage I and 418.9 cm 3 (range 140.3 to
762.6 cm3) for stage III tumors. OARs were delineated
including heart and contra-lateral lung. The clinical
quality of the VMAT plans was assessed using 45 stage I
lung patients (average PTV 35.4 cm3; range 5.5 to
175.4 cm3 ) and 73 stage III lung patients (average PTV
344.4 cm3; range 25.1 to 1069.0 cm3).
Treatment planning
For the algorithm comparison, optimal VMAT plans
were prepared using AAA algorithm grid size 2.5 mm
consisting of two 180 degrees arcs using the VMAT
optimization tool. Dose prescription was 54 Gy in 5 frac-
tions to the 80% isodose, which covered at least 99% of
the PTV, for stage I, and for stage III 66 Gy in 33 frac-
tions, where at least 99% of the PTV received 90% of the
prescribed dose. For stage III, an additional constraint of
D≤1% = 72.6 Gy (110% of prescribed dose) was used and
the dose to OARs, such as lung and heart, was opti-
mized. The plans were recalculated using the same beam
settings and monitor units as the AAA grid size 2.5 mm
treatment plans for AAA grid size 1.0 mm, AXB grid
size 2.5 mm and AXB grid size 1.0 mm.
In the VMAT optimization process, a Clinical Protocol
was used (and if necessary, optimized interactively) with
Optimization Objectives for the PTV, heart, lungs and
spinal cord (with a margin of 5 mm). Most dose volume
histogram (DVH) objectives had a priority of 50, whereas
the minimum and maximum PTV dose, defined as D100%
and D0%, had a priority of 250 and the maximum spinal
cord dose (10 Gy for stage I and 44 Gy for stage III) had a
priority of 150 or 200. For stage III VMAT plans, a MLD
objective of 12 Gy with a priority of 200 was applied; and
a contra-lateral lung dose V5Gy-cont objective of 30% or
25% was used with a priority of respectively 450 or 500 for
the 73 stage III patients. This study used the volume of
both lungs minus internal target volume (ITV) for the cal-
culation of MLD, and volume of both lungs minus PTVfor V20Gy, and V5Gy. Most of the time, we applied a
“Normal Tissue Objective” with a fall-off of 4 for stage I
stereotactic treatments and of 1 for stage III conven-
tional lung treatments. A help volume with a margin of
5 mm around the PTV was introduced with also re-
latively high priorities when OARs were not spared suf-
ficiently. It was almost never necessary to include
constraints for the other OARs.
Evaluation tools
Dose volume histograms were produced for all plans in
order to analyze the doses to the PTV and OARs. The
statistical differences were tested for the VMAT treat-
ment plans between AAA grid size 2.5 mm, AAA grid
size 1.0 mm, AXB grid size 2.5 mm and AXB grid size
1.0 mm. The statistical significance of the differences
was tested with a paired two-tailed student t-test with
significant level p < 0.05.
Results and discussion
Justification of the assumption that AXB represents the
real dose distribution
The analyses in this study to cross-check the findings by
Bush et al. [22] confirmed that AXB is much more ac-
curate in heterogeneous situations than AAA (Figure 1).
For single fields, there were no large differences between
grid size 2.5 mm and grid size 1.0 mm. The relative
doses were much higher for AAA than AXB in the mid-
dle low density layer (ρ = 0.03 g cm-3) of the interface
phantom. The difference in relative doses were even
larger than 20% for a field size of 1.0×1.0 cm2 and larger
than 10% for a field size of 4.0×4.0 cm2. Bush et al. [22]
have also published large relative dose differences, e.g.
larger than 30% for a very low density media (ρ =
0.001 g cm-3) and a field size of 4.0×4.0 cm2.
Therefore, it is now shown by simulations and measure-
ments that calculations using AXB represent better the
actual delivered dose distribution in case of narrow beams
and heterogeneous situations than AAA. Of course, in
most patients real lung density will be larger than the low
density taken in this study (ρ = 0.03 g cm-3), and differences
between AXB and AAA will be smaller as also stated by
Bush et al. [22].
Dosimetric impact of algorithms and grid sizes on clinical
lung VMAT plans
Dose volume histograms were produced for all plans so
that the relative differences between algorithms (AAA and
AXB) and grid sizes (2.5 and 1.0 mm) could be analyzed.
The dose calculation time by AAA grid size 1.0 mm in
comparison to AAA grid size 2.5 mm, AXB grid size
2.5 mm and AXB grid size 1.0 was much larger. For ex-
ample for stage I, the calculation times were 7, 10 and 3
times larger with AAA grid size 1.0 mm in comparison to
Figure 1 Measured and calculated percentage depth dose curves in a slab-phantom. Predicted percentage depth dose curves by AAA and
Acuros XB grid sizes 2.5 and 1.0 mm compared to measured data using a slab-phantom with (top) 1.0x1.0 cm2 and (bottom) 4.0x4.0 cm2 6 MV
AP photon beams.
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grid size 1.0 mm. We have decided to focus on the dose
distribution differences between AAA grid size 2.5 mm
and AXB grid size 2.5 mm; and on the dose distribution
differences between AXB grid size 2.5 mm and AXB grid
size 1.0 mm since AAA grid size 1.0 mm will probably
never be used clinically and the differences with AAA grid
size 2.5 mm were very small.
A summary of the relative dose differences between
algorithms and grid sizes is given in Table 1. For individual
stage I lung patients differences occurred in dose distribu-
tions between AXB and AAA. The maximum difference
of near-minimum PTV dose (D98%) between AXB grid
size 2.5 mm and AAA grid size 2.5 mm was −7.1 Gy
corresponding to a relative difference of −12.3%, which
indicated a serious underdosage of the delivered dose
when this patient would have been planned with the AAA
algorithm (Table 1, Figure 2). This finding is similar to re-
sults published by Gete et al. [23]. They observed a 12.8%
lower minimum PTV dose using Monte Carlo simulations
than using AAA version 8.6 calculations for one patient
plan. These relative differences can be explained by the
significantly improved accuracy of AXB under the con-
ditions of electronic disequilibrium compared to AAA.
AAA only predicts little secondary build-up at regions
beyond low-density media like lung [22,26,27].
AXB showed a slightly but significant (p < 0.05) higher
V20Gy (volume of both lungs minus PTV with a dose of
20 Gy or more) value than AAA for stage I patients. Asa result, AAA grid size 2.5 mm treatment plans might
be clinically approved with the real V20Gy being slightly
too high. The differences in lung doses calculated by
AAA and AXB were patient dependent since they were
dependent on field size, location of the target inside the
lung and the density of the lung. Depending on the ac-
tual combination of field size, target location and lung
density, AAA can over- or underestimate the lung dose,
as also stated by Bush et al. [22]. The relative dose differ-
ences between both models for the other OARs were
small. However, there was a large difference in calculation
time between both algorithms. The dose calculation times
required by AAA grid size 2.5 mm were about 2 times the
calculation times required by AXB grid size 2.5 mm.
In case of stage III patients, the difference in PTV
doses were smaller than in case of stage I patients
(Table 1, Figure 1) due to, e.g. larger fields and tumor
sizes, resulting in smaller errors in the AAA algorithm.
The differences in OAR doses were also small. There
was again a significant (p < 0.01) difference in calculation
time between AAA and AXB. The average final dose
calculation time was respectively, 6 and 4 minutes, for
AAA grid size 2.5 mm and AXB grid size 2.5 mm.
Only small significant differences were found between
AXB grid size 2.5 mm and AXB grid size 1.0 mm for
near-maximum PTV dose (D2%) (Table 1, Figure 2),
while the calculation time will increase drastically when
grid size 1.0 mm was used instead of grid size 2.5 mm.
The average calculation time was 2 and 8 minutes for
Table 1 Relative differences between algorithms and grid sizes for lung cancer patients
Relative difference p-value Relative difference p-value
(AXB2.5 -AAA2.5)/ AAA2.5×100% (AXB1.0 - AXB2.5)/ AXB2.5×100%
Average ± SDV (min-max) Average ± SDV (min-max)
Stage I (N = 8)
PTV
D98% −3.2% ± 4.0% (−12.3% – 0.5%) 0.06 0.7% ± 1.3% (−0.8% – 3.1%) 0.19
D2% 0.2% ± 1.2% (−2.1% – 1.3%) 0.69 0.9% ± 0.4% (0.3% – 1.4%) <0.01
*
Dmean −0.6% ± 2.2% (−4.9% – 1.6%) 0.46 0.2% ± 0.5% (−0.6% – 1.2%) 0.45
Total lung
V5Gy 1.3% ± 1.9% (−1.9% –3.2%) 0.12 0.1% ± 0.6% (−0.8% – 1.1%) 0.73
V20Gy 2.0% ± 2.3% (0.0% – 5.7%) 0.05
* −0.7% ± 1.2% (−2.7% – 0.0%) 0.17
MLD 0.0% ± 0.5% (−0.7% – 0.7%) 0.60 0.1% ± 0.2% (0.0% – 0.4%) 0.08
Time
Calculation −39.2% ± 13.5% (−50.3% – –8.2%) <0.01* 304.7% ± 48.7% (226.9% – 345.8%) <0.01*
Stage III (N = 7)
PTV
D98% −0.3% ± 0.7% (−0.8% – 1.3%) 0.33 0.2% ± 0.8% (−1.4% – 0.9%) 0.57
D2% −0.6% ± 2.0% (−2.1% – 3.0%) 0.47 0.6% ± 0.4% (−0.1% – 1.0%) <0.01
*
Dmean −0.8% ± 0.7% (−1.6% – 0.3%) 0.02
* 0.1% ± 0.3% (−0.5% – 0.4%) 0.40
Total lung
V5Gy −1.8% ± 1.7% (−4.8% – 0.3%) 0.03
* −0.4% ± 0.7% (−1.5% – 0.4%) 0.16
V20Gy 0.2% ± 0.7% (−0.5% – 1.5%) 0.69 0.0% ± 0.0% (0.0% –0.0%) 1.00
MLD −0.5% ± 0.6% (−1.3% – 0.0%) 0.09 0.2% ± 0.3% (0.0% – 0.6% ) 0.17
Time
Calculation −31.4% ± 9.9% (−44.4% – –17.9%) <0.01* 556.9% ± 91.1% (412.3% – 646.0%) <0.01*
*Significant relative difference tested by two-tailed student t-test.
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spectively, and 4 and 27 minutes for stage III patients
with grid size 2.5 mm and 1.0 mm.
Therefore, we recommend using AXB grid size 2.5 mm
for VMAT planning of lung tumors, since this results in
accurate dose values with acceptable calculation times.
Clinical quality of VMAT
The dose volume quantities of 45 stage I and 73 stage III
lung patients planned with VMAT AXB grid size 2.5 mm
were analyzed. The average MLD, total lung V20Gy and
total lung V5Gy were 3.6 Gy, 4.1% and 15.7% for stage I
and 12.4 Gy, 19.3% and 46.6% for stage III. The pre-
scribed dose of 66 Gy could be delivered to all patients.
The MLD was between 16.0 and 18.5 Gy for 15% of the
stage III patients, for all other patients, the MLD was
lower than 16 Gy.
It was difficult to compare the obtained plan qualities
with literature since different patients were used. How-
ever, when we compared the dose volume quantities
with published studies about VMAT techniques for stage
I and stage III NSCLC patients [2,3,16,28], we concludedthat the plan qualities were at least comparable. For
example, McGrath et al. [3] have published an average
MLD for stage I tumors of 4.6 Gy (with dose prescrip-
tion: 99% of the PTVITV has to receive more than
43.2 Gy) with VMAT. In our study the average MLD
was 3.6 Gy (with a higher dose description: 99% of the
PTV has to receive more than 54.0 Gy).
For stage III patients, the clinical quality of treatment
plans is a trade-off between high doses to gross tumour
volume and limiting treatment related pneumonitis
(TRP). Doses higher than 64 Gy are preferred [13] which
could be obtained for all 73 clinical patients in this
study. Simultaneously, lung doses should be minimized
since these influenced the post-radiation acute TRP. Sev-
eral studies describe analyses to determine indicators for
predicting TRP [29-33]. Different predictors were indi-
cated in these studies, e.g. V5Gy-cont by Song et al. [29],
V5Gy by Wang et al. [30], MLD and V30Gy by Kim et al.
[31], and V10Gy by Shi et al. [32] and Spych et al. [33].
Song et al. [29] have shown with an extensive multivari-
ate analysis including V5Gy, V10Gy, V13Gy, V15Gy, V20Gy
and MLD for total lung, ipsilateral lung and contra-
Figure 2 Dose volume histogram comparisons of PTV doses between algorithms and grid sizes. Comparison of dose volume histograms
of the planning target volume (PTV) between AAA grid size 2.5 mm, Acuros XB grid size 2.5 mm and Acuros XB grid size 1.0 mm of (top) a stage
I and (bottom) a stage III lung patient. The black vertical lines indicate the prescription: The dose that has to cover 99% of the PTV, respectively,
54.0 Gy for stage I and 59.4 Gy for stage III.
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cant factor associated with TRP. They concluded that
V5Gy-cont should be kept as low as possible and they sug-
gested a cut-off value of 60% since incidences of grade ≥ 3
pneumonitis were 35% and 0%, respectively, for V5Gy-cont ≤
60% and V5Gy-cont > 60% (p = 0.01).
In this study, a V5Gy-cont planning objective of 30% or
25% was used with priority of 450 or 500 for the 73 stage
III patients planned with VMAT. Adding this objective
decreased significantly the MLD, V5Gy and V5Gy-cont (p <
0.01) from 12.7 Gy, 53.5% and 47.7% to 12.4 Gy, 46.6%
and 35.6%, respectively. The V5Gy-cont was larger than 60%Table 2 Comparison of stage III VMAT and hybrid-VMAT plan
Study Method N Dprescibed [Gy] VPT
De Bree-Balk et al. [14]1 VMAT 20 66
Verbakel et al. [15]2 VMAT 14 66
H-VMAT 14 66
Chan et al. [16]3 VMAT 24 60
H-VMAT 24 60
This study4 VMAT 73 66
This study4 VPTV > 500 cm
3 VMAT 13 66
Average values and standard deviations are given.
1 [14] Use the volume of both lungs minus CTV for MLD and V20Gy; PTV V95% > 99%
2 [15] Use the volume of both lungs minus PTV for V20Gy; PTV V95% > 97% and PTV V
3 [16] Use the volume of both lungs minus PTV for MLD, V20Gy and V5Gy; D98% > 57.0
4 This study uses the volume of both lungs minus ITV for MLD, and volume of both
PTV V90% > 99% and PTV V110% ≤ 1%.
5 Median instead of average value is given.for only one patient. Kim et al. [31] have used a MLD cut-
off value of 16 Gy and indicated that the actual incidence
of lung toxicity of grade ≥ 2 was 8% for MLD ≤ 16 Gy and
54% for MLD > 16 Gy (p < 0.01). Wang et al. [30] have de-
termined an incidence of grade ≥ 3 TRP at 1 year of 13%
for MLD ≤ 16.5 Gy and of 36% for MLD >16.5 Gy (p =
0.02). We have obtained a MLD ≤ 16.5 Gy for 90.4% of the
patients and the maximum MLD was 18.3 Gy.
The lung dose values, MLD, V20Gy, V5Gy and V5Gy-cont
were compared to lung dose values published in the
literature using VMAT and hybrid-VMAT techniques. It
is shown in Table 2 that the clinical VMAT plans of thiss
V [cm
3] MLD [Gy] V20Gy [%] V5Gy [%] V5Gy-cont [%]
8385 20.0 36.6 NA 69.6
779 NA 30.3 ± 5.7 NA 44.6 ± 9.0
779 NA 30.1 ± 5.8 NA 36.2 ± 15.0
508 14.4 ± 2.9 25.4 ± 6.0 64.0 ± 15.4 NA
508 14.0 ± 2.9 23.3 ± 5.3 59.5 ± 16.7 NA
344 12.4 ± 3.5 19.3 ± 6.8 46.6 ± 10.6 35.6 ± 7.1
678 14.5 ± 2.1 22.1 ± 6.4 52.1 ± 10.3 38.7 ± 10.0
and PTV V107% < 1%.
107% < 5%.
Gy and D2% < 64.2 Gy.
lungs minus PTV for V20Gy and V5Gy.
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with VMAT and hybrid-VMAT discussed in literature
[14-16]. Historically, all our stage III plans were
normalised as: 99% of the PTV is covered by 90% of the
prescribed dose (66 Gy). Our normalisation is in close
agreement with the recommended normalisation method
by ICRU 83 [34], to the mean PTV dose. For our stage III
patients, the mean PTV dose was 101.2% ± 1.4%. This im-
plies that our normal tissue DVH values will even be
slightly better when we use ICRU 83 for normalisation in
the future.
This study illustrates that it is possible with two 180
degree arcs to obtain clinical plan qualities compared to
VMAT and hybrid-VMAT plans described in literature.
Generating acceptable plans using VMAT with two arcs of
180 degrees required only 1 hour for plan optimization and
dose calculations. Consequently, our clinical VMAT plans
show comparable clinical plan quality as hybrid VMAT
techniques, therefore being a quick and easy alternative.
Conclusions
We investigated the quality of VMAT treatment plans
using Eclipse treatment planning system version 10.0 for
stage I and III lung patients. All plans consisted of 2
partial arcs of 180 degrees. We showed that the AXB
calculation algorithm was preferable to AAA since pos-
sible PTV underdosage, as a result of inaccurate AAA
calculations, can be avoided. In addition, the calculation
time was much shorter for AXB. For clinical VMAT
lung plans, the quality and accuracy of AXB grid size
2.5 mm was comparable with AXB grid size 1.0 mm.
However, the calculation time increases drastically when
grid size 1.0 mm was used.
The VMAT plans were compared to published treat-
ment planning studies. The clinical VMAT AXB grid size
2.5 mm plans obtained in this study were at least compar-
able to the published planning studies, e.g. planned with
hybrid-VMAT, therefore being a quick and easy alterna-
tive for this technique.
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